


BRIEF COMMUNICATION OPEN



Vision within the blind spot: a new test to quantify melanopsin pathway sensitivity

Jeff Rabin¹ , Jewearly Lundby¹, Madison Brase¹, Ally Vu¹, Austin Millis¹, Grant Wood¹, Dorin Huq¹ and Erica Poole¹

© The Author(s) 2024

Eye; <https://doi.org/10.1038/s41433-024-03102-4>

The physiological blind spot (BS) is the spatial projection of the optic nerve head wherein ganglion cell axons collect to form the optic nerve. The BS is 15.5° temporal to fixation, 5.5° wide by 7° high. Since the optic nerve head lacks photoreceptors, the BS is presumed to be an absolute scotoma readily mapped on tangent screen, but perceptually filled-in during normal viewing. Intrinsically photosensitive sensitive retinal ganglion cells (ipRGCs) absorb light with melanopsin mediating pupil

responses, photoentrainment, cognition, alertness, and vision [1–4]. Since ipRGC axons contain melanopsin, they may respond to appropriate stimulation in the BS [4]. Our purpose was to: (1) determine whether vision can occur within the BS via ipRGCs (2) exploit this epiphenomenon to develop a rapid test of melanopsin pathway sensitivity.

30 healthy adults provided written informed consent to participate in our IRB approved protocol (mean age±SD: 27±9).





Fig. 1 The Blind Spot Vision Test. **A** An extract from the Blind Spot Vision Test (BSVT) shown diagrammatically. With left eye occluded, the observer is seated before the display with right eye directly in front of the red X (top). The observer moves her/his head fore/aft until the red oval disappears and maintains the head at the approximate midpoint of the range of red oval disappearance. The next trial (middle) displays the green oval to ensure that it disappears as well. The next trial displays the ipRGC optimized blue oval and the observer reports if anything is seen and to describe its color. This was followed by the method of limits to determine the lowest blue luminance perceived (mean of three trials). **B** The reader may wish to experience disappearance of the red and green ovals followed by appearance of a less well-formed bluish glow or similar percept by following the steps described for Fig. 1A coupled with moving the head up and down or the computer image. It is recommended that this be conducted in a dark setting. Due to changes in chromaticity and luminance in the published images, this demonstration may not be optimal for the reader.

¹University of the Incarnate Word Rosenberg School of Optometry, San Antonio, TX, USA. email: rabin@uiwtx.edu

Received: 29 December 2023 Revised: 12 April 2024 Accepted: 19 April 2024

Published online: 02 May 2024




Fig. 2 Normative Values for the Blind Spot Vision Test. **A** The mean ipRGC luminance detection threshold and 95% CI (± 2 SD) is plotted (log value equivalent to 32 cd/m^2) for 30 visually normal subjects to establish an initial normative database. Three subjects, tested in the same manner but in the nasal field where the BS is not present, showed red, green and blue thresholds $>100\times$ lower than the putative ipRGC thresholds in the BSVT consistent with much higher sensitivity of cone and/or rod photoreceptors (mediating temporal retina detection) compared to ipRGCs [1–5]. **B** Bland-Altman plot showing the pooled differences in ipRGC threshold for each subject's right and left eye plotted against their means. The mean difference ($-0.01 \log \text{cd}/\text{m}^2$) is represented by the bold line and the dotted lines represent upper and lower limits of the COR ($0.11 \log \text{cd}/\text{m}^2$). Hence the COR represents the 95% confidence interval for within patient change; a difference exceeding 0.11 is considered significant. Like normative data, the COR is essential for serially monitoring of patients over time.

Visual acuity, contrast sensitivity, and Ishihara testing verified normal vision and color vision. The Blind Spot Vision Test (BSVT, Fig. 1) was displayed on a Microsoft Surface in a dark room with left eye occluded. The subject's right eye was centred before a red X (left side of black display viewed at 50–60 cm). The blind spot target was a $1.4^\circ \times 2.5^\circ$ vertical oval 15° temporal to fixation. The first stimulus was red followed by a green oval each $12.7 \text{ cd}/\text{m}^2$. The subject moved fore/aft until the red oval disappeared followed by green oval disappearance to ensure targets were in the BS. This blue oval ($41.2 \text{ cd}/\text{m}^2$, CIE $x, y = 0.206, 0.278$, dominant wavelength 480 nm, melanopsin peak) [1–3] was presented next. In response to the blue oval, subjects reported if anything appeared and its perceived color. The method of descending/ascending limits was used to determine three blue target thresholds by changing luminance up/down in 0.05 log steps. Mean, confidence intervals (CI), and the coefficient of repeatability (COR) were calculated from pooled data.

After BS determination (red, green oval disappearance) 100% reported reappearance of a light blue haze or glow in response to the blue oval. Two subjects tested at closer and farther distances reported that the glow became a well-formed peripheral blue oval suggesting cone mediation at distances outside the BS. Mean ± 2 SD ipRGC BSVT threshold was $32.0 \pm 12.6 \text{ cd}/\text{m}^2$ ($1.5 \pm 0.2 \log \text{cd}/\text{m}^2$, Fig. 2A). The COR was $0.11 \log \text{cd}/\text{m}^2$ (95% CI for within-subject change, Fig. 2B). Red, green, and blue thresholds from three subjects to stimuli 15° nasal to fixation were $> 100\times$ lower than BSVT thresholds substantiating mediation of the BSVT by less sensitive ipRGCs [1–4].

Subject limitations include possible artifacts from fixational shifts or subject reliability which could be mitigated by fixation monitoring and catch trials. The results do support visual perception within the BS with stimuli optimized for ipRGCs. Testing across a blue luminance range yielded repeatable thresholds providing a metric of ipRGC pathway sensitivity. Potential applications include detection/monitoring of ocular, systemic and/or neurologic disease, and mood, alertness, pupil, and circadian rhythm function. BSVT testing may also serve as an outcome measure for gene therapy efficacy in eye disease [5].

REFERENCES

- Hattar S, Liao H, Takao M, Berson D, Yau K. Melanopsin-containing retinal ganglion cells: Architecture, projections, and intrinsic photosensitivity. *Science*. 2002;295:1065–70. <https://doi.org/10.1126/science.1069609>

- Mure LS, Vinberg F, Hanneken A, Panda S. Functional diversity of human intrinsically photosensitive retinal ganglion cells. *Science*. 2019;366:1251–55. <https://doi.org/10.1126/science.aaz0898>
- Rabin J, Poole E, Price W, Kaur G, Hall K, Sailors V, et al. A new method to quantify the human visual threshold from melanopsin sensitive ganglion cells. *Front Cell Neurosci*. 2023;17:1132230. <https://doi.org/10.3389/fncel.2023.1132230>
- Schilling T, Soltanlou M, Nuerk HC, Bahmani H. Blue-light stimulation of the blind-spot constricts the pupil and enhances contrast sensitivity. *PLoS ONE*. 2023;18:e0286503. <https://doi.org/10.1371/journal.pone.0286503>. 2023
- De Silva S, Barnard A, Hughes S, Tam S, Martin C, Singh MS, et al. Long-term restoration of visual function in end-stage retinal degeneration using subretinal human melanopsin gene therapy. *Proc Natl Acad Sci USA*. 2017;114:11211–6. <https://doi.org/10.1073/pnas.1701589114>

AUTHOR CONTRIBUTIONS

JR was responsible for conducting the search, designing/writing the protocol, data collection, statistical analyses, results interpretation, writing the manuscript, and research oversight. JL was responsible for conducting the search, designing/writing the protocol, data collection, statistical analyses, results interpretation, and writing the manuscript. MB, AV, AM, GW, DH, EP were responsible for designing the protocol, data collection, collating data, and results interpretation. Contributions and Access to Data: The Principal Investigator, Dr. Jeff Rabin, had full access to all the data and takes responsibility for the integrity of the data and the accuracy of the data analysis.

FUNDING

Research reported in this publication was supported by the National Eye Institute of the National Institutes of Health under Award Number T35EY032441. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Open access funding provided by SCEL, Statewide California Electronic Library Consortium.

COMPETING INTERESTS

The authors declare no competing interests.

ADDITIONAL INFORMATION

Correspondence and requests for materials should be addressed to Jeff Rabin.

Reprints and permission information is available at <http://www.nature.com/reprints>

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2024